B7-1/CD80 Antibody (galiximab) - Chimeric

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28253

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # galiximab

Concentration

LYOPH mg/ml

View all B7-1/CD80 Antibodies »

Product Specifications

Immunogen

CD28L / CD80

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.

Also known as 'galiximab'.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Applications for B7-1/CD80 Antibody (galiximab) - Chimeric

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: B7-1/CD80

The B-lymphocyte activation antigen B7-1 (CD80) provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells. After engagement of T-cell receptor with antigen in association with major histocompatibility complex class II, a second signal mediated through the binding of B7 to CD28 greatly upregulates the production of multiple lymphokines (1). The relatively small CTLA-4/B7-1 binding interface exhibits an unusually high degree of shape complementarity. CTLA-4 forms homodimers through a newly defined interface of highly conserved residues. This zipper-like oligomerization provides the structural basis for forming unusually stable signalling complexes at the T-cell surface, underscoring the importance of potent inhibitory signalling in human immune responses (2).

Alternate Names

B71, CD80

Gene Symbol

CD80

UniProt

P33681

Additional B7-1/CD80 Products

Product Documents for B7-1/CD80 Antibody (galiximab) - Chimeric

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for B7-1/CD80 Antibody (galiximab) - Chimeric

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.